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In a paper last year in Archives of Toxicology, “Toxi-
cological comments to the discussion about REACH”,
a group of distinguished European community toxicol-
ogists (Greim et al. 2006) expressed their opinions on
discussions about the extent to which in vitro studies
and considerations of structure activity relationships
provide suYcient information to waive repeated expo-
sure studies in animals. The authors argued that critical
data needed for hazard identiWcation and risk assess-
ment can only be developed by conducting repeat dose
studies in animals. They consider the data sets from
these studies to be essential for risk assessment. In
their abstract, they note that, “The evidence that avail-
able alternatives would support such replacement is
weak. Progress to improve their value for risk assess-
ment purposes is bound to be slow because the issues
are very complex. As a group of European toxicologist
we strongly support the need for more research sup-
port in these areas, but we believe that over claims for
progress is damaging their development.”
We appreciate the concerns raised about too rapid
replacement of these repeat studies without a clear path
for how data sets from in vitro or SAR evaluations
would supplant these more traditional toxicity studies.
However, we disagree strongly with the conclusions of
the commentary on the state of development of these
methods for decision making. More importantly, we
feel compelled to take exception with several points
presented or inferences made in this paper. The points
that require some discussion are: (1) current testing/risk
assessment strategies represent an optimal approach
for making decisions regarding human health risks of
chemicals; (2) the goal of a replacement is to develop
tests that provide perfect correspondence with the cur-
rent in vivo toxicity testing approaches; (3) in vitro
methods cannot provide information regarding dose–
response necessary for risk assessments; and (4)
approaches to introduce new methods for toxicity test-
ing and risk assessment reXect consideration of cost
reduction and decreased animal use rather than deci-
sions taken on the basis of toxicological considerations.
We brieXy discuss each point below.
Current testing/risk assessment strategies represent 
an optimal approach for making decisions regarding 
human health risks of chemicals
The current testing strategies, relying almost exclu-
sively on results from animal studies, are an amalgam
of testing requirements developed piecemeal starting
in the mid-1900s. These studies utilize the highest tol-
erated doses in multiple animal species and develop
dose–response curves to assess no observed eVect
(NOEL) or no observed adverse eVect levels
(NOAEL) for a variety of physiological endpoints.
These approaches may be widely accepted, but they
are not at all validated for the purposes of predicting
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386 Arch Toxicol (2007) 81:385–387human health risks. Together with safety factors, these
NOAELs and NOELs may provide reassurance to
many that there will be little risks in exposed humans.
However, it is simply wrong to consider animal toxicity
tests as some gold standard against which all in vitro or
in silico methods will be judged.
The goal of a replacement is to develop tests that 
provide perfect correspondence with the current 
in vivo toxicity testing approaches
The goal of toxicity testing, however it is pursued, is to
insure safety of chemicals (or the presence of no more
than some very small, societally tolerable level of risk)
in exposed human populations. However, new methods
and new paradigms are necessary to achieve this end.
Tests systems need to be designed to answer questions
regarding the pathways that are aVected by chemicals;
whether these pathways are as likely to be aVected in
humans as in the test system; the physiological conse-
quences of alterations in these pathways; and the over-
all dose response curve for the eVects. In this way
in vitro test systems or in silico methods are not simply
alternatives to animal tests, nor are they intended to
be replacements for animal tests. Instead, they are
intended to give speciWc answers to questions regarding
hazards of chemical exposures expected in human pop-
ulations. These new methods represent improvements
on the present approaches, not some lesser position to
be taken in the absence of available animal tests.
In vitro methods cannot provide information regarding 
dose–response necessary for risk assessments
The animal tests provide a dose response curve for the
eVects in these test animals. Only one point of this
curve, i.e., the NOAEL/NOEL is used. Methods used
for predicting lower dose responses, such as dividing by
various uncertainty factors, are no more than conven-
tions propped by tradition rather than informed predic-
tions based on knowledge of the biology of the
responses. How can these risk estimates be made more
relevant for assessing expected consequences of expo-
sures in humans? Another way to pose the question is:
how will toxicity testing take into consideration the
mode of action and relevant measures of tissue dose for
risk extrapolations? We and others evaluating new tox-
icity testing strategies believe that the answer here is the
development of high throughput systems that examine
speciWc precursor responses, i.e., speciWc response bio-
markers, in appropriate in vitro test systems.
Today, the Weld of contemporary toxicity testing
needs well-validated suites of cellular systems that
examine relevant biomarkers for critical physiological
eVects (Eisenbrand et al. 2002). Ideally, these biomar-
kers would enable the reliable estimation of precursor
responses with known relevance for an adverse end-
point in humans. The consideration of these adverse
endpoints will dictate the selection of appropriate
in vitro cellular test systems. Such decisions can be
facilitated by knowledge of the structural information
on the presence of chemical functionalities known to
be related to the endpoints of concern (i.e., QSAR
methods).
The outcome of these carefully conducted in vitro
tests would be the cellular response characteristics for
the precursor response/biomarker over a wide concen-
tration range. These in vitro approaches yield much
denser dose–response relationships covering a broader
range of concentrations than for those developed from
animal testing. These studies would provide data-rich
concentration– (or an internal dose–) response rela-
tionships. Finally, these relationships serve as the basis
for calculating the external dose (or human exposure
scenario) leading to the concentrations used in vitro.
These in vitro to in vivo extrapolations can be done by
the application of physiologically-based biokinetic
modeling (Andersen 2003), a Weld that has been exten-
sively explored by one of us (Blaauboer 2003). The
result of such approaches will be a better estimation of
the internal eVective concentration at the target sites in
humans than can be reached with studies in animals.
It is clear from this outline that the elements of this
approach, i.e., the in vitro, in silico, and computational
components, need to be placed in the framework of a
comprehensive testing strategy. Hence, the notion that
these elements will be replacing current animal models
on a one-to-one basis is overly simplistic and impedes
innovation.
Approaches to introduce new methods for toxicity 
testing and risk assessment reXect consideration 
of cost reduction and decreased animal use rather 
than decisions taken on the basis of toxicological 
considerations
On the contrary, the introduction of these new toxicity
testing methodologies is intended to improve current
risk assessment processes, making them more relevant
by incorporating mechanistic information, accounting
for diVerences in dose between in vitro and in vivo con-
ditions, and focusing on human relevance (Goldberg
and Hartung 2005). During the last decade a number of123
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tics of the above-described, strategic approaches
(DeJongh et al. 1999; Gubbels-van Hal et al. 2005; Ver-
wei et al. 2006). Although these studies had limitations
and shortcomings, they showed that the concept is fea-
sible. Estimates were made of the exposure scenarios
that result in toxic reactions in vivo on the basis of
information from in vitro toxicity testing, QSARs and
kinetic modeling. It is also clear from these studies,
that there should be more emphasis on human models
rather than simply observing the exposures leading to
adverse eVects in animals. This redeWnition of toxicity
testing is absolutely necessary for improving human
risk assessment. We look forward to replacing the so-
called “gold standard” of animal toxicity testing by a
strategy resulting in a more targeted risk analysis for
human health endpoints. The time is ripe to move on
to a platinum standard for toxicity testing.
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